Abivax
ABVX
258 hedge funds and large institutions have $5.53B invested in Abivax in 2026 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 114 increasing their positions, 75 reducing their positions, and 44 closing their positions.
63% more call options, than puts
Call options by funds: $233M | Put options by funds: $142M
52% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 75
23% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 44
3% more funds holding
Funds holding: 250 → 258 (+8)
9.04% less ownership
Funds ownership: 72.26% → 63.22% (-9%)
18% less funds holding in top 10
Funds holding in top 10: 34 → 28 (-6)
55% less capital inflows, than outflows
Capital inflows: $647M | Capital outflows: $1.43B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Helikon Investments
London,
United Kingdom
|
+$120M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$37M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$34.3M |
| 4 |
Eversept Partners
New York
|
+$32.7M |
| 5 |
Logos Global Management
San Francisco,
California
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$210M |
| 2 |
Morgan Stanley
New York
|
-$171M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$103M |
| 4 |
Paradigm Biocapital Advisors
New York
|
-$76.3M |
| 5 |
TCG Crossover Management
Palo Alto,
California
|
-$74.6M |
ABVX Hedge Fund Activity: Q1 2026 in Review
258 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q1 2026, worth a combined $5.53B — down 27% from $7.61B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ABVX positions and 44 closed out — a net gain of 10 holders — while 114 added to existing stakes and 75 trimmed.
The largest buyer was Helikon Investments, opening a new position worth an estimated $120M. The largest seller was Point72 Asset Management, cutting an estimated $210M.
- 258 institutional investors held Abivax (ABVX) as of Q1 2026, up from 250 in Q4 2025.
- Funds reported $5.53B of Abivax stock for Q1 2026, down 27% quarter-over-quarter.
- 54 funds opened new Abivax positions in Q1 2026 and 44 closed out, a net change of +10 holders.
- The largest Abivax buyer in Q1 2026 was Helikon Investments, an estimated $120M added.
- The largest Abivax seller in Q1 2026 was Point72 Asset Management, an estimated $210M sold.
Based on aggregated 13F filings for Q1 2026.